KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Cited by (1,002)

Items 601–700 of 1,002

1. Mutations in the α4-α5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association
   Michael Whaby, Lauren Wallon, Megan Mazzei, Imran Khan, Kai Wen Teng, Shohei Koide, John P. O’Bryan · 2022 · Journal of Biological Chemistry
2. Validation of an LC–MS/MS method for the determination of sotorasib, a KRAS G12C inhibitor, in human plasma
   Philip S. H. Wong, Anna Akrami, Brett E. Houk, Irene Vuu, Christopher A. James · 2022 · Bioanalysis
3. KRAS inhibition in metastatic colorectal cancer: An update
   Maliha Nusrat, Rona D. Yaeger · 2023 · Current Opinion in Pharmacology
4. miR-4739 promotes epithelial-mesenchymal transition and angiogenesis in “driver gene-negative” non-small cell lung cancer via activating the Wnt/β-catenin signaling
   Wen‐Jian Cen, Qin Yan, Wenpeng Zhou, Minjie Mao, Qitao Huang, Yaobin Lin, Neng Jiang · 2023 · Cellular Oncology
5. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment
   Rebecca A. Shuford, Ashley Cairns, Omeed Moaven · 2020 · Cancers
6. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
   Maruyama, Kohei, Shimizu, Yuki, Nomura, Yumi, Oh-hara, Tomoko, Takahashi, Yuki, Nagayama, Satoshi, Fujita, Naoya, Katayama, Ryohei · 2025 · npj Precision Oncology
7. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome
   Julie A. Vendrell, Xavier Quantin, Audrey Aussel, Isabelle Solassol, Isabelle Serre, Jérôme Solassol · 2021 · Translational Lung Cancer Research
8. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors
   Aslamuzzaman Kazi, Alok Ranjan, Vasantha Kumar M.V., Bogos Agianian, Martin Garcia Chavez, Vignesh Vudatha, Rui Wang, Rajanikanth Vangipurapu, Liwei Chen, Perry Kennedy et al. · 2023 · Cancer Research Communications
9. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
   Yu Zhang, Liang Liu, Jinpeng Pei, Zhiqiang Ren, Yan Deng, Ker Yu · 2024 · Oncogene
10. Harnessing ferroptosis for enhanced sarcoma treatment: mechanisms, progress and prospects
    Jing Zeng, Xianghong Zhang, Zhengjun Lin, Yu Zhang, Jing Yang, Pengcheng Dou, Tang Liu · 2024 · Experimental Hematology and Oncology
11. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
    Rafael Rosell, Eloisa Jantus Lewintre, Peng Cao, Xueting Cai, B. Xing, Masaoki Ito, Jose Luis Gomez-Vazquez, Mireia Marco-Jordán, Silvia Calabuig Fariñas, Andrés Felipe Cardona et al. · 2024 · Cell Communication and Signaling
12. Current perspectives of KRAS in non-small cell lung cancer
    Ethan Harris, Rajat Thawani · 2024 · Current Problems in Cancer
13. An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer
    Ateş Kutay Tenekeci, Ahmet Arda Unal, Furkan Ceylan, Mehmet Ali Nahit Sendur · 2024 · Future Oncology
14. Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC
    Angel A. Dominguez, M Perz, Yi Xu, Leonor G. Cedillo, O L Huang, Caitlin A. McIntyre, Vignesh Vudatha, Jose Gilberto Trevino, Jun Liu, Pei Wang · 2024 · Cancers
15. Pancreatic ductal adenocarcinoma in the era of precision medicine
    Binbin Zheng-Lin, Eileen Mary O'Reilly · 2021 · Seminars in Oncology
16. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
    Arsela Prelaj, Chiara Carlotta Pircher, Giacomo Massa, Valentino Martelli, Giulia Corrao, Giuseppe Lo Russo, Claudia Proto, Roberto Ferrara, Giulia Galli, Alessandro De Toma et al. · 2021 · Cancers
17. D154Q Mutation does not Alter KRAS Dimerization
    Ingrid Grozavu, Sarah E. Stuart, Anna Lyakisheva, Zhong Yao, Shivanthy Pathmanathan, Michael Ohh, Igor Štagljar · 2021 · Journal of Molecular Biology
18. Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
    SungGi Chi, Yosuke Minami · 2022 · International Journal of Molecular Sciences
19. KRAS Mutation in Rare Tumors: A Landscape Analysis of 3453 Chinese Patients
    Shuhang Wang, Qin Li, Peiwen Ma, Yuan Fang, Yue Yu, Ning Jiang, Huilei Miao, Qiyu Tang, Yuqi Yang, Shujun Xing et al. · 2022 · Frontiers in Molecular Biosciences
20. Artificial Intelligence–Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Non–Small-Cell Lung Cancer
    Jonghanne Park, Hyung-Gyo Cho, Jewel Park, Grace Lee, Hye Sung Kim, Kyunghyun Paeng, Sanghoon Song, Gahee Park, Chan‐Young Ock, Young Kwang Chae · 2022 · American Journal Of Pathology
21. Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma
    Xiaonan Wu, Jun Zhao, Ling Yang, Xin Nie, Zheng Wang, Ping Zhang, Chao Li, Xueqing Hu, Min Tang, Yuting Yi et al. · 2022 · Journal of Cancer
22. Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
    Irene S. Yu, Francine Aubin, Rachel Anne Goodwin, Jonathan M. Loree, Cheryl A. Mather, Brandon S. Sheffield, Stephanie Leann Snow, Sharlene Gill · 2022 · Therapeutic Advances in Medical Oncology
23. Degradation of Rat Sarcoma Proteins Targeting the Post-Translational Prenyl Modifications via Cascade Azidation/Fluorination and Click Reaction
    Hongling Zhou, Youfang Gan, Yuanyuan Li, Xiaoqian Chen, Yuyang Guo, Rui Wang · 2023 · Journal of Medicinal Chemistry
24. Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
    Yoshimura, Akihiro, Horinaka, Mano, Yaoi, Takeshi, Ono, Hisako, Itoh, Kyoko, Yamada, Tadaaki, Takayama, Koichi, Sakai, Toshiyuki · 2024 · British Journal of Cancer
25. Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis
    Yubo Jiang, Gang Mai, Xiaokai Zhao, Meng Xiong Tang, Pengmin Yang, Qian Cheng, He Tian, Zuoxing Niu, Xintao Wang, Jiao Wang et al. · 2025 · npj Precision Oncology
26. Targeting the Ras pathway in pediatric hematologic malignancies
    Yana Pikman, Elliot Stieglitz · 2020 · Current Opinion in Pediatrics
27. Inhibiting mutant KRAS G12D gene expression using novel peptide nucleic acid‑based antisense: A potential new drug candidate for pancreatic cancer
    Shai, Ayelet, Galouk, Evleen, Miari, Reem, Tareef, Hala, Sammar, Marei, Zeidan, Mouhammad, Rayan, Anwar, Falah, Mizied · 2022 · Oncology Letters
28. RNA splicing alterations in lung cancer pathogenesis and therapy
    Yueren Yan, Yunpeng Ren, Yufang Bao, Yongbo Wang · 2023 · Cancer Pathogenesis and Therapy
29. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study
    Lian Yu, Jianlin Xu, Rong Qiao, Hua Zhong, Wolfgang Michael Brueckl, Runbo Zhong · 2023 · Translational Lung Cancer Research
30. The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches
    Dimitrios Nasioudis, Marta Llauradó, Nelson K.Y. Wong, Daniel J. Powell, Gordon Brent Mills, Shannon Neville Westin, Amanda N. Fader, Mark Stafford Carey, Fiona A. Simpkins · 2023 · Gynecologic Oncology
31. Prognostic potential of whole exome sequencing in the clinical management of metachronous colorectal cancer liver metastases
    Lucie Heczko, Viktor Hlaváč, Petr Holý, Pavel Dvořák, Václav Liška, Ondřej Vyčítal, Ondřej Fiala, Pavel Souček · 2023 · Cancer Cell International
32. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
    Hang Cao, Zelin Ma, Qingyuan Huang, Han Han, Yuan Li, Yang Zhang, Haiquan Chen · 2024 · European Journal of Cancer
33. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma
    Ke Cheng, Zijian Zhou, Qiangxing Chen, Zixin Chen, Yu Cai, He Cai, Shangdi Wu, Pan Gao, Yunqiang Cai, Jin Rong Zhou et al. · 2024 · Scientific Reports
34. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
    Quentin Dominique Thomas, Xavier Quantin, Pablo Lemercier, CHRISTOS CHOUAID, Sophie Schneider, Thomas Filleron, Jordi Remon-Masip, Maurice Pérol, Didier Debieuvre, Clarisse Audigier-Valette et al. · 2024 · ESMO Open
35. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
    Jacob Edward Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M. Pfeiffer, Jaclyn Paige Lyman, Lacey Padrón, Deena M. Maurer, Jia Xin Yu, Christine N. Spencer et al. · 2024 · Nature Communications
36. Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery
    Leticia Manen-Freixa, Albert A. Antolín · 2024 · Expert Opinion on Drug Discovery
37. Unravelling the diagnostic pathology and molecular biomarkers in lung cancer
    Andriani G. Charpidou, Georgia F. Hardavella, Efimia Boutsikou, Εmmanouil Panagiotou, Gökçen Ömeroğlu Şi̇mşek, Koen Verbeke, Daniela Xhemalaj, Joanna J. Domagala-Kulawik · 2024 · Breathe
38. Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRASG12C, are associated with renal toxicity in the Sprague Dawley rat
    Jonathan A. Werner, Rhian Davies, Jan L. Wahlstrom, Upendra P. Dahal, Min Jiang, Jonathan Stauber, Benjamin David, William D. Siska, Barbara Thomas, Katsu Ishida et al. · 2021 · Toxicology and Applied Pharmacology
39. The Mutational Landscape of Myeloid Leukaemia in Down Syndrome
    Carini Picardi Morais de Castro, Maria Cadefau-Fabregat, Sergi Cuartero · 2021 · Cancers
40. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
    Satoshi Nagayama, Siew‐Kee Low, Kazuma Kiyotani, Yusuke Nakamura · 2021 · Cancers
41. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
    Nabih Naim, Sara Moukheiber, Samah Daou, Hampig Raphaël Kourié · 2021 · Critical Reviews in Oncology/Hematology
42. Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc
    Alexander Chan, Hejia Henry Wang, Rebecca M. Haley, Cindy Song, David Gonzalez-Martinez, Lukasz J. Bugaj, Michael J. Mitchell, Andrew Tsourkas · 2022 · Molecular Pharmaceutics
43. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes
    Takehiko Tsumura, Keitaro Doi, Hiroyuki Marusawa · 2022 · Cancers
44. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples
    Miriam Redegalli, Greta Grassini, Gilda Magliacane, Lorenza Pecciarini, Marco Schiavo Lena, Chanel Elisha Smart, Rebecca L. Johnston, Nicola Waddell, Roberta Maestro, Marina Macchini et al. · 2022 · Clinical Gastroenterology and Hepatology
45. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun
    Maristella Bungaro, Silvia Novello, Francesco Passiglia · 2022 · Current Treatment Options in Oncology
46. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features
    Hang Cao, Zelin Ma, Yuan Li, Yang Zhang, Haiquan Chen · 2023 · Journal of Thoracic and Cardiovascular Surgery
47. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer
    Andrea S. Fung, Donna M. Graham, Eric Xueyu Chen, Tracy L. Stockley, Tong Zhang, Lisa W. Le, Hamzeh Albaba, Katherine M.W. Pisters, Penelope A. Bradbury, Martina A. Trinkaus et al. · 2021 · Lung Cancer
48. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families
    Li, Lianbo, Meyer, Cynthia, Zhou, Zhi-Wei, Elmezayen, Ammar, Westover, Kenneth · 2022 · Journal of Molecular Biology
49. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML
    Bogdan Popescu, Matthew F. Jones, Madison Piao, Elaine Tran, Andrew Koh, Isabelle Lomeli, Cheryl A.C. Peretz, Natália Faraj Murad, Sydney Abelson, Carolina E. Morales et al. · 2025 · Blood
50. Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC
    Timothy Francis Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama, Philippe Alexandre Cassier, Antoîne Italiano, Ji‐Youn Han, Nimit Singhal, Shinji Takeuchi et al. · 2025 · Journal of Thoracic Oncology
51. Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
    Yoon Jung Jang, Dong‐gon Hyun, Chang‐Min Choi, Ki Hyeong Lee, Sang‐We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji, Jae Cheol Lee · 2021 · BMC Cancer
52. Strategies for Targeting KRAS: A Challenging Drug Target
    Abdul Wadood, Amar Ajmal, Ashfaq Ur Rehman · 2022 · Current Pharmaceutical Design
53. Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
    Yuchan Li, Omar Elakad, Sha Yao, Alexander Freiherr von Hammerstein-Equord, Marc Hinterthaner, Bernhard Christoph Danner, Carmelo Ferrai, Philipp Ströbel, Stefan Küffer, Hanibal Bohnenberger · 2022 · Metabolites
54. Top advances of the year: Precision oncology
    Aakash P. Desai, Neha K. Reddy, Vivek Subbiah · 2023 · Cancer
55. Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer
    Li-Bo Tang, Ruiyang Li, Huahai Wen, Qing Hua Zhou, Chong‐Rui Xu · 2023 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
56. Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment
    Vidhi M. Shah, Syed Zaki Husain Rizvi, Alexander Smith, Motoyuki Tsuda, Madeline Krieger, Carl Pelz, Kevin MacPherson, Jenny Eng, Koei Chin, Michael W. Munks et al. · 2023 · Pharmaceutics
57. Biomarker Testing Disparities in Metastatic Colorectal Cancer
    Saad Sabbagh, María Herrán, Ali Hijazi, Iktej Singh Jabbal, Mohamed Mohanna, Barbara Geraldine Dominguez, Mira Itani, Kaylee Sarna, Hong Liang, Zeina A. Nahleh et al. · 2024 · JAMA Network Open
58. Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
    Hirotaka Miyashita, David S. Hong · 2024 · Journal of Cancer Immunology
59. SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers
    Johanna Lilja, Jasmin Kaivola, James R. W. Conway, Joni Vuorio, Hanna Parkkola, Pekka Roivas, Michal Dibus, Megan R. Chastney, Taru Varila, Guillaume Jacquemet et al. · 2024 · Nature Communications
60. KRASMutations in Cholangiocarcinoma: Prevalence, Prognostic Value, andKRASG12/G13 Detection in Cell-Free DNA
    PITCHASAK THONGYOO, Jarin Chindaprasirt, Chaiwat Aphivatanasiri, Piyapharom Intarawichian, Waritta Kunprom, Sarinya Kongpetch, Anchalee Techasen, Watcharin Loilome, Nisana Namwat, Attapol Titapun et al. · 2024 · Cancer Genomics & Proteomics
61. Identification of Candidate Alterations Mediating KRAS G12C Inhibitor Resistance in Advanced Colorectal and Pancreatic Cancers
    Khalid Jazieh, Jill Tsai, Sheila R. Solomon, Mojun Zhu, Frank A. Sinicrope, Katrina Sophia Pedersen, Martín E. Fernández-Zapico, Hao Xie · 2025 · Clinical Cancer Research
62. Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer
    Tao Yuan, Yue Liu, Ruilin Wu, Meijia Qian, Weihua Wang, Yonghao Li, Hongdao Zhu, Jia’er Wang, Fujing Ge, Chenming Zeng et al. · 2025 · Nature Communications
63. The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer
    Dilara Akhoundova, Joaquín Mosquera, L. E. Musmann, Christian Britschgi, Cyrill Rütsche, Markus Rechsteiner, Ernest Nadal, M.R. García Campelo, Alessandra Curioni Fontecedro · 2020 · Journal of Clinical Medicine
64. Future directions in drug development in pancreatic cancer
    Aurélien Lambert, Thierry Conroy, Michel Pierre Ducreux · 2021 · Seminars in Oncology
65. Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy
    Juan Ruiz Bañobre, Ajay Goel · 2021 · Advances in cancer research
66. Génotypage moléculaire dans les cancers réfractaires de la thyroïde en 2021 : quand, comment, et pourquoi ? Un travail du réseau TUTHYREF
    Christelle de la Fouchardière, Johanna Wassermann, Fabien Calcagno, Stéphane Bardet, Abir Al Ghuzlan, Isabelle Borget, Françoise Borson‐Chazot, Christine Do Cao, Camille Buffet, Slimane Zerdoud et al. · 2021 · Bulletin du Cancer
67. Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers
    Arnaud Bayle, Debora Basile, Simon Garinet, Bastien Rance, Pierre Laurent‐Puig, Hélène Blons, Julien Taı̈eb, Géraldine Perkins · 2021 · Cancers
68. Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
    Abdulaziz A. Almotlak, Mariya Farooqui, Adam C. Soloff, Jill M. Siegfried, Laura P. Stabile · 2021 · International Journal of Molecular Sciences
69. Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling
    Thomas Jens Ettrich, Niklas Sturm, Melanie Güthle, Felix Jakob Hüttner, Lukas Perkhofer · 2022 · Visceral Medicine
70. ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability
    Nancy H.C. Loos, Irene A. Retmana, Wenlong Li, Margarida L.F. Martins, Maria Cristina Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel · 2022 · Pharmacological Research
71. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
    Christophe Bontoux, Véronique Hofman, Patrick Brest, Marius Ilié, Baharia Mograbi, Paul M Hofman · 2022 · Cancers
72. Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy
    Gerardo Rosati, Giuseppe Aprile, Alfredo Colombo, Stefano Sergio Cordio, Marianna Giampaglia, Alessandro Cappetta, Concetta Maria Porretto, Alfonso De Stefano, Domenico Bilancia, Antonio Avallone · 2022 · Biomedicines
73. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
    Alessia Spagnuolo, Paolo Maione, Cesare Gridelli · 2022 · Translational Lung Cancer Research
74. Targeting KRAS : Crossroads of Signaling and Immune Inhibition
    Shumei Kato, Yu Fujiwara, David S. Hong · 2022 · Journal of Immunotherapy and Precision Oncology
75. Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives
    Mahmoud Toulany · 2022 · Clinical and Translational Radiation Oncology
76. Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
    Manxiong Dai, Raja Jahanzaib, Yan Liao, Fengxuan Yao, Jia Li, Xiong Teng, Kang Chen, Wei Cheng · 2022 · Frontiers in Oncology
77. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies
    Bennett Adam Caughey, John H. Strickler · 2023 · Drugs
78. Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer
    Rodrigo de Oliveira Cavagna, Flávia Escremim de Paula, Débora Sant'Anna, Iara Viana Vidigal Santana, Vinícius Duval da Silva, Eduardo Caetano Albino da Silva, Carlos E. Bacchi, José Elias Miziara, Josiane Mourão Dias, Pedro De Marchi et al. · 2021 · JCO Global Oncology
79. Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentation?
    Yuko Oya, Tetsuya Mitsudomi · 2023 · Translational Lung Cancer Research
80. Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
    Murciano-Goroff, Yonina R., Hollebecque, Antoine, Heist, Rebecca S., Cassier, Philippe A., Han, Ji-Youn, Kim, So Yeon, Sabari, Joshua K., Tosi, Diego, Sacher, Adrian, Burns, Timothy F. et al. · 2026 · Nature Communications
81. Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
    Ferdinandos Skoulidis, Bob T. Li, Maximilian Johannes Hochmair, Ramaswamy Govindan, Mark David Vincent, Anthonie J. van der Wekken, Noemi Reguart Aransay, Kenneth John O'Byrne, Nicolas Girard, Frank Griesinger et al. · 2025 · The Oncologist
82. Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers
    Kenjiro Iida, Yuuki Matsui, Y. Urabe, T. Muramatsu, Juntaro Matsuzaki, Yoshimasa Saito · 2025 · ESMO Open
83. High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models
    Juan Carlos Álvarez-Pérez, Juan Sanjuán‐Hidalgo, Alberto M. Arenas, Ivan Hernández-Navas, Maria S. Benitez‐Cantos, Álvaro Andrades, Silvia Calabuig Fariñas, Eloisa Jantus Lewintre, Luis G Paz-Ares, Irene Ferrer et al. · 2025 · Nature Communications
84. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant
    Zhe Zhang, Xiaobo Wang, Jiajun Ye, Huanhuan Liu, Jianyang Fang, Mingru Zhang, Yesen Li, Jinxiong Huang, Deliang Zhang, Jing Wang et al. · 2021 · Molecular Pharmaceutics
85. Targeting KRAS Regulation with PolyPurine Reverse Hoogsteen Oligonucleotides
    Alexandra Maria Psaras, Simonas Valiuska, Verónique Noé, Carlos J. Ciudad, Tracy Ann Brooks · 2022 · International Journal of Molecular Sciences
86. Targeting Myeloid-Derived Suppressor Cell Trafficking as a Novel Immunotherapeutic Approach in Microsatellite Stable Colorectal Cancer
    Benny Johnson · 2023 · Cancers
87. Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
    İbrahim Halil Şahin, Turçin Saridogan, Rüveyda Ayasun, Masood Pasha Syed, Vikram C. Gorantla, Monica Khunger Malhotra, Roby Antony Thomas, John C. Rhee, Janie Yue Zhang, Dennis J. Hsu et al. · 2024 · JCO Oncology Practice
88. A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-Driven Non–small Cell Lung Cancer
    Cima Cina, Bharat Kumar Majeti, Zhihong O’Brien, Li Wang, Jean‐Pierre Clamme, Roger C. Adami, Kwok Yin Tsang, Jens Harborth, Wenbin Ying, Sonya Zabludoff · 2024 · Molecular Cancer Therapeutics
89. Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies
    Ruilin Wu, Hong Zhu, Qiaojun He, Tao Yuan, Bo Yang · 2024 · Drug Discovery Today
90. First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives
    Qi He, Xiaoyan Liu, Liyan Jiang, Ping Liu, Weixia Xuan, Yudong Wang, Rui Meng, Huijing Feng, Shuang Lv, Qian Miao et al. · 2024 · Cancer Biology & Therapy
91. Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
    Tuan Anh Hoang, Erica S. Tsang · 2025 · Journal of Gastrointestinal Cancer
92. RAS Pathway Mutations and Therapeutics in Vascular Anomalies
    Sara Alharbi, Svatava Merkle, Adrienne M. Hammill, Andrew M. Waters, Timothy D. Le Cras · 2025 · Pediatric Blood & Cancer
93. Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers
    Zhao Liu, Yiqi Li, Simeng Wang, Yubo Wang, Mengjun Sui, Jiaxin Liu, Pu Chen, Jianling Wang, Yuchen Zhang, Chengxue Dang et al. · 2025 · Journal of Experimental & Clinical Cancer Research
94. Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review
    Sara El Zaitouni, Abdelilah Laraqui, Youssra Boustany, Soukaina Benmokhtar, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Safae El Kochri, El Arbi Bouaiti, Idriss Lahlou Amine et al. · 2025 · Clinical Medicine Insights Oncology
95. Recent advances in therapeutic targeting of the KRAS pathway in cancer
    Nadia Hitchen, Sarah Williams, Jayesh Desai · 2025 · Pharmacology & Therapeutics
96. Smart drug delivery platforms reprogramming cancer immune cycle to mitigate immune resistance of pancreatic tumors
    Ping Zhang, Jiaxing Pan, Shutong Lin, Bo Peng, Junjing Zhang, Junjing Zhang, Leiming Xu, Yi Ling Lai, Haijun Yu, Zhiai Xu · 2025 · Advanced Drug Delivery Reviews
97. Generative AI - Assisted Adaptive Cancer Therapy
    Youcef Derbal · 2025 · Cancer Control
98. Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids
    Paloma Navarro, Tatiana P. Grazioso, Arántzazu Barquín, Maria Barba, Mónica Yagüe, Carlos Millán, Irene López, Elena Sevillano, Miguel Quiralte, Paloma Fernández et al. · 2025 · Journal of Experimental & Clinical Cancer Research
99. Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer
    Hiroyuki Sayama, Diana H. Marcantonio, Takeyuki Nagashima, Masashi Shimazaki, Tsuyoshi Minematsu, Joshua F. Apgar, John M. Burke, Lucia Wille, Yasuhisa Nagasaka, Daniel C. Kirouac · 2021 · CPT Pharmacometrics & Systems Pharmacology
100. Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling
     Yanping Li, Xiaoqian Xiao, Huili Wang, Qi Zhou, Zhao Yang Jin, Yuxi Zhang, Yi Wang, Fuping Yue, Shiyi Zhou, Jiahui Yang · 2021 · European Journal of Pharmacology